Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

eXoZymes Inc. - Common Stock (NQ:EXOZ)

9.700 -0.290 (-2.90%)
Streaming Delayed Price Updated: 12:37 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about eXoZymes Inc. - Common Stock

eXoZymes Provides Second Quarter 2025 Update at 5PM EST Today
Via ACCESS Newswire
eXoZymes to Host Second Quarter 2025 Update on Tuesday August 12, 2025, at 5PM EST
Via ACCESS Newswire
eXoZymes Details Biomanufacturing Breakthrough: 4 Grams of NCT with Over 99% Purity
Via ACCESS Newswire
eXoZymes Biomanufacturing Breakthrough: From Concept to Gram-Scale NCT in Only 5 Months
Via ACCESS Newswire
eXoZymes Selected as Core Industry Partner in $9M NSF-Funded Initiative to Advance Modular Cell-Free Biomanufacturing
Via ACCESS Newswire
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
eXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout, NCTx, on Grow Everything Podcast
Via ACCESS Newswire
eXoZymes Provides First Quarter 2025 and NCTx Subsidiary Update at 5PM EST Today
Via ACCESS Newswire
eXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM EST
Via ACCESS Newswire
eXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver Health
Via ACCESS Newswire
Bringing clarity and precision to the cell-free space by introducing exozymes
From eXoZymes Inc.
Via GlobeNewswire
New to The Street's FOX Business "Late Night T.V." Special Airs Tonight – Show #650 – Featuring Health In Tech CEO Julia Qian (NASDAQ:HIT), BioVie's Dr. Joseph Palumbo (NASDAQ:BIVI), eXoZymes Co-Founder & VP of Research Tyler Korman (EXOZ), and ARRIVE AI
Via ACCESS Newswire
BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant
From eXoZymes Inc.
Via GlobeNewswire
eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO
From eXoZymes Inc.
Via GlobeNewswire
eXoZymes Provides Fourth Quarter and Full Year 2024 Update
From eXoZymes Inc.
Via GlobeNewswire
Earnings Scheduled For April 2, 2025
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025
From eXoZymes Inc.
Via GlobeNewswire
New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle.com With Craig Bruce
Via ACCESS Newswire
eXoZymes and MDB Capital Announce Leadership Transition at eXoZymes Inc.
From eXoZymes Inc.
Via GlobeNewswire
eXoZymes Announces Nasdaq Bell Ringing to Commemorate Initial Public Offering
From eXoZymes Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.